BMS’ P-III (CheckMate -8HW) Study of Opdivo (nivolumab) + Yervoy (ipilimumab) for MSI-H/dMMR mCRC Attains Primary Endpoint
Shots: The company’s P-III (CheckMate -8HW) study met the dual 1EP of PFS in...
Kymera Therapeutics and Sanofi Report First Patient Dosing with KT-474 in P-II Trial for the Treatment of Atopic Dermatitis
Shots: The first patient was dosed in the P-II (ADVANTA) trial evaluating the safe...
Merck Discontinues the P-III (KEYLYNK-008) Study of Keytruda (pembrolizumab) + Lynparza (olaparib) for Metastatic Squamous NSCLC
Shots: Merck has halted its P-III (KEYLYNK-008) study, as suggested by an independ...
Sanofi Reports Results for Sarclisa (Isatuximab) in P-III Trial for the Treatment of Newly Diagnosed Multiple Myeloma Patients
Shots: The P-III (IMROZ) clinical trial evaluates Sarclisa (10mg/kg, IV, qw) + VRd...
Merck KGaA Reports Results for Evobrutinib in P-III Trial for the Treatment of Relapsing Multiple Sclerosis (RMS)
Shots: The P-III (EVOLUTION) clinical trials incl. (evolutionRMS 1) & (evoluti...
Genentech Reports the Results of Inavolisib Combination Therapy in P-III Trial for the Treatment of Breast Cancer
Shots: The P-III (INAVO120) clinical trial evaluates the safety & efficacy of...
